- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07454967
Développement d'un système d'IA multimodal pour la gestion du GIST
Développement et Validation d'un Modèle d'Intelligence Artificielle Multimodal Intégrant la Radiomique TDM, la Pathomique et les Caractéristiques Cliniques pour le Diagnostic, la Stratification du Risque et la Prédiction du Génotype des Tumeurs Stromales Gastro-Intestinales
Background: Gastrointestinal Stromal Tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Accurate pre-operative diagnosis, risk stratification, and genotyping are critical for determining the appropriate surgical approach and targeted therapy (such as Imatinib). However, current methods often rely on invasive postoperative pathology and expensive genetic testing.
Study Objective: The purpose of this study is to develop and validate a multimodal Artificial Intelligence (AI) model that integrates clinical data, CT radiomics (imaging features), and pathomics (digital pathology features) to improve the precision of GIST management.
Study Design: This is a prospective, observational study. The researchers will recruit patients with suspected gastric submucosal tumors who are scheduled for surgery or biopsy at The Fourth Hospital of Hebei Medical University.
Core Tasks: The AI model will be trained to perform three specific tasks:
Diagnosis: Distinguish GISTs from other non-GIST mesenchymal tumors (e.g., leiomyomas, schwannomas).
Risk Assessment: Stratify GISTs into risk categories (e.g., Low vs. High risk) to predict malignant potential.
Genotyping: Predict specific gene mutations (e.g., KIT or PDGFRA mutations) to guide immunotherapy or targeted therapy.
Methodology: Patient data (CT scans, pathology slides, and clinical history) will be collected and analyzed by the AI system. The AI's predictions will be compared against the "Gold Standard" results derived from postoperative pathological examination and Next-Generation Sequencing (NGS). This study is non-interventional; the AI results will not affect the standard of care received by the patients.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Anhui
-
Fuyang, Anhui, Chine, 236003
- The Fifth Affiliated Hospital of Anhui Medical University
-
-
Hebei
-
Baoding, Hebei, Chine, 071030
- Baoding Central Hospital
-
Cangzhou, Hebei, Chine, 061000
- Cangzhou People's Hospital
-
Hengshui, Hebei, Chine, 053099
- Hengshui People's Hospital
-
Shijiazhuang, Hebei, Chine, 050011
- Shijiazhuang People's Hospital
-
Xingtai, Hebei, Chine, 054000
- The Second Affiliated Hospital of Xingtai Medical College
-
-
Hubei
-
Wuhan, Hubei, Chine, 430065
- Renmin Hospital of Wuhan University
-
-
Hunan
-
Hengyang, Hunan, Chine, 421001
- The First Affiliated Hospital of University of South China
-
-
Jiangsu
-
Nanjing, Jiangsu, Chine, 210002
- Jinling Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patients presenting with gastric submucosal tumors (SMTs) who are admitted to the Department of Gastrointestinal Surgery at The Fourth Hospital of Hebei Medical University for surgical or endoscopic treatment. The cohort includes patients with subsequently pathologically confirmed GISTs and other mesenchymal tumors (e.g., leiomyoma, schwannoma).
La description
Inclusion Criteria:
Age ≥ 18 years, gender not limited.
Clinical diagnosis of gastric submucosal tumor (SMT) or suspected gastrointestinal stromal tumor (GIST) based on gastroscopy or ultrasound.
Scheduled for surgical resection or endoscopic biopsy at the study center.
Standard preoperative contrast-enhanced CT scans are available (performed within 2 weeks prior to surgery).
Patients or their legal guardians have signed the informed consent form.
Exclusion Criteria:
Received neoadjuvant therapy (e.g., Imatinib, chemotherapy, or radiotherapy) prior to surgery/biopsy.
Poor quality of CT images (e.g., severe motion artifacts) affecting radiomics analysis.
Insufficient tissue samples for pathological diagnosis or genetic testing.
Confirmed diagnosis of other primary malignancies.
Incomplete clinical data or lost to follow-up immediately after surgery.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Diagnostic Accuracy of the AI Model for Distinguishing GIST from Non-GIST Tumors
Délai: Up to 30 days post-surgery
|
The diagnostic accuracy is calculated as the proportion of correctly classified patients (GIST vs. Non-GIST) by the multimodal AI model, compared to the gold standard postoperative pathological diagnosis. |
Up to 30 days post-surgery
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Concordance Rate between AI-predicted Risk Grade and Pathological Modified NIH Criteria
Délai: Up to 30 days post-surgery
|
The proportion of patients whose risk category (Very Low/Low vs. Intermediate/High) predicted by the AI model matches the actual risk grade determined by postoperative pathology according to the modified National Institutes of Health (NIH) criteria. This will be reported as a percentage (0-100%) |
Up to 30 days post-surgery
|
|
Sensitivity and Specificity of the AI Model in Predicting KIT/PDGFRA Gene Mutations
Délai: Up to 30 days post-surgery
|
The AI model's performance in identifying specific mutations (e.g., KIT exon 11, PDGFRA) compared to the results of Next-Generation Sequencing (NGS). Data will be reported as percentages with 95% confidence intervals. |
Up to 30 days post-surgery
|
|
Area Under the Receiver Operating Characteristic Curve (AUC) for All Tasks
Délai: Up to 30 days post-surgery
|
The AUC values will be calculated to evaluate the overall performance of the AI model in diagnosis, risk stratification, and genotype prediction. Sensitivity and Specificity will also be reported. |
Up to 30 days post-surgery
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- GIST-DX-RISK-GEN-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .